Tumor regression by means of magnetic drug targeting
The expression 'magnetic drug targeting' is understood as meaning the targeted administration of a drug, for example, a cytostatic, with the intention of optimizing the local therapeutic effect. A magnetic field strength of 0.6 T is applied externally to the body. Iron oxides are administered intravasally into a vein. Cytostatics are bonded to the iron oxides. This form of administration, also known as sluicing, is particularly suitable for cytostatics, since the intention is to achieve a high concentration of the cytostatic at the target site (site of the tumor), but to minimize the harmful effect in the rest of the tissue. A reduction in tumor volume under the magnetic field and in the liver of 45-90% has been detected by MRI.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 4(2009), 8 vom: 15. Dez., Seite 875-82 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Krukemeyer, M G [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 03.03.2010 Date Revised 25.11.2016 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2217/nnm.09.73 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM193247151 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM193247151 | ||
| 003 | DE-627 | ||
| 005 | 20231223194425.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2009 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm.09.73 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0644.xml |
| 035 | |a (DE-627)NLM193247151 | ||
| 035 | |a (NLM)19958224 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Krukemeyer, M G |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tumor regression by means of magnetic drug targeting |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 03.03.2010 | ||
| 500 | |a Date Revised 25.11.2016 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The expression 'magnetic drug targeting' is understood as meaning the targeted administration of a drug, for example, a cytostatic, with the intention of optimizing the local therapeutic effect. A magnetic field strength of 0.6 T is applied externally to the body. Iron oxides are administered intravasally into a vein. Cytostatics are bonded to the iron oxides. This form of administration, also known as sluicing, is particularly suitable for cytostatics, since the intention is to achieve a high concentration of the cytostatic at the target site (site of the tumor), but to minimize the harmful effect in the rest of the tissue. A reduction in tumor volume under the magnetic field and in the liver of 45-90% has been detected by MRI | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Wagner, W |e verfasserin |4 aut | |
| 700 | 1 | |a Jakobs, M |e verfasserin |4 aut | |
| 700 | 1 | |a Krenn, V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 4(2009), 8 vom: 15. Dez., Seite 875-82 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2009 |g number:8 |g day:15 |g month:12 |g pages:875-82 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nnm.09.73 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2009 |e 8 |b 15 |c 12 |h 875-82 | ||